The study by researchers at the Davis Institute (LDI), led by researchers at the General Department (JGH), includes the atlas of genetic factors associated with estimated bone density (BMD), one of the most clinically relevant factors in osteoporosis diagnosis. Paper Released Genetic NatureIt identifies 518 genome-wide loci, of which 301 are newly discovered, which accounts for 20% of genetic variance associated with osteoporosis. Some of the genetic factors that have been identified have demonstrated the development of novel novels aimed at reducing the risk of treating illness and reducing risk.
"Our findings show significant progress in highlighting drug development opportunities," said Dr. Brent Richards, a lead researcher, a genetist at the LDI Clinical Epidemiology Center, which deals with osteoporosis in practice with JGH. "The genetic modification of the BMD provides drug targets that help to prevent osteoporotic fractures".
Osteoporosis begins with a very common bone strength, which causes a high risk of fracture. In older patients, in particular, the fracture may have serious consequences, including death risk. In all patients, fractures include large burdens of hospitalization and rehabilitation. Depending on the population age, the need to improve preventative measures is even faster.
"Today we have little treatment options," said Dr. Richards, Professor of Medicine, Human Genetics, and Epidemiology and Bioestatistics at McGill University, "and many of the risk-breaking patients are not afraid of current medication because of side effects. However, treatment It's better than avoiding it – we can prescribe injections of extraction of the bones, but they are prohibitively expensive. We have medications that prevent bone loss, but they need strict time, but the result is not very high for people who need to be treated. We will be able to make it easier for patients to follow a treatment regime ".
The genetic determinant of osteoporosis was the largest ever study, evaluating more than 426,000 people in the UK Biobank. After analyzing the data, the researchers have established more findings to isolate isolation of high-wealthy gene targeting drugs. Smaller target groups of genes will be able to find a solution to the clinical problem that drug developers face to prevent the fractures of people with osteoporotic fractures. Animal models have shown that some of these genes are valid.
"Although we have found a lot of genetic factors associated with BMD, the genetic make-up of medical precision has to include factors that could have the greatest impact on bone density and reduce the risk of rupture," said Dr. John, the chief author of research at Morris, LDI and McGill University.
Cataracts associated with dangers of osteoporosis and fracture
The Atlas of Genetic Impacts of Osteoporosis for Men and Moms, Genetic Nature (2018). DOI: 10.1038 / s41588-018-0302-x, https://www.nature.com/articles/s41588-018-0302-x